Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes

This study is comparing two treatment approaches for people with advanced colorectal cancer that has spread and no longer responds to standard chemotherapy. One arm combines hydroxychloroquine (a drug used for autoimmune conditions) with methotrexate, capecitabine, and bevacizumab; the other uses regorafenib, a standard last-line therapy. **You may be eligible if...** - You are 18 years or older - You have metastatic colorectal cancer with a KRAS or NRAS gene mutation - Your cancer has progressed after at least 2 prior chemotherapy regimens including oxaliplatin and irinotecan - You are in relatively good health and can perform daily activities (ECOG 0-1) **You may NOT be eligible if...** - You have significant heart problems, a recent heart attack, or uncontrolled high blood pressure - You have had a recent stroke or transient ischemic attack (TIA) - You have significant kidney or liver disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.